Anti-Hu CD23 Pacific Blue™

*Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13 (15 Pt 1) :4448-55., URL: https://pubmed.ncbi.nlm.nih.gov/17671129/, *Rumi C, Rutella S, Leone G, Bonini S: Fc-RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1;91 (7) :2621-2., URL: http://www.ncbi.nlm.nih.gov/pubmed/9516167 , *Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL) . Clin Exp Immunol. 1991 Dec;86 (3) :360-6., URL: http://www.ncbi.nlm.nih.gov/pubmed?term=stevenson%20fk%20ling%20nr, *Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr;8 (4) :479-90., URL: http://www.ncbi.nlm.nih.gov/pubmed?term=yamaoka%20ka%20arock%20m , *Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy. 2005 May 20;3:6., URL: http://www.ncbi.nlm.nih.gov/pubmed/15907205 , *Quardokus EM, Saunders DC, McDonough E, Hickey JW, Werlein C, Surrette C, Rajbhandari P, Martinez Casals A, Tian H, Lowery L, Neumann EK, Björklund F, Neelakantan TV, Croteau J, Wiblin AE, Fisher J, Livengood AJ, Dowell KG, Silverstein JC, Spraggins JM, Pryhuber GS, Deutsch G, Ginty F, Nolan GP, Melov S, Jonigk D, Caldwell MA, Vlachos IS, Mueller W, Gehlenborg N, Stockwell BR, Lundberg E, Snyder MP, Germain RN, Camarillo JM, Kelleher NL, Börner K, Radtke AJ: Organ mapping antibody panels: a community resource for standardized multiplexed tissue imaging. Nat Methods 2023 Aug;20 (8) :1174-1178. doi: 10.1038/s41592-023-01846-7., URL: https://pubmed.ncbi.nlm.nih.gov/37468619/

The mouse monoclonal antibody EBVCS-5 recognizes an extracellular epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.